No Data
No Data
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Exscientia Acquires Oral CDK7 Inhibitor for $20m, Plans Breast Cancer Trial
Exscientia to Acquire Full Rights to Lead Asset
Exscientia Shares Down On Unchanged Cash Runway Expectations After Acquisition
By Sabela Ojea Shares of Exscientia fell Thursday after the company said it still expects to have cash runway to continue operating into 2027 following its latest acquisition. The stock was down 3.6%
Exscientia to Acquire Full Control of Cancer Drug Program From GT Apeiron
Exscientia (EXAI) said on Thursday it is acquiring GT Apeiron's stake in its cancer drug program, gaining full control of GTAEXS617 and associated intellectual property.The company said the
Exscientia Secures Full Rights to Novel Cancer Drug
No Data